Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

HPLC purity vs. LC-MS identity: why one test cannot replace the other

Name: HPLC purity vs. LC-MS identity: why one test cannot replace the other
Published: 2026-10-27

What each lab method actually measures, and how a wrong or impure product can pass one test and fail the other

Evidence verdict: Based on analytical-chemistry literature, FDA impurity guidance and the published Open Peptide Standard. This is a method explainer, not a product rating. [4, 1]

Last reviewed: Oct 27, 2026

In 30 seconds

RP-HPLC with UV detection separates a sample and reports the main peak as a percentage of the total UV signal. That is a purity figure, not proof of what the peak is. [1, 2]
LC-MS weighs the molecules and checks that the measured mass matches the expected peptide. That confirms identity, but on its own it does not tell you how pure the product is or how much peptide is in the vial. [1, 3]
A product can show a clean, high HPLC purity and still be the wrong peptide. A product can also have the right mass and still contain fillers or impurities that LC-MS was not set up to quantify. [2, 3, 4]
That is why the Open Peptide Standard treats identity by LC-MS and purity by RP-HPLC as separate required tests, and makes a failed identity an automatic Fail. [1]

What HPLC purity means

Reversed-phase HPLC pushes the dissolved sample through a column, and molecules come out at different times. A UV detector, usually set around 214–220 nm for the peptide backbone, draws a peak for each. "Purity" is the area of the main peak divided by the area of all peaks the detector saw. [1] [Lab, Policy] Two limits follow. First, the percentage only covers what absorbs UV: in one analysis, quantitative NMR found undeclared mannitol making up 20% and 43% by weight of two commercially sourced custom peptides, which routine LC methods had not flagged. [2] [Lab] Second, the main peak is assumed to be the right peptide. HPLC alone cannot prove that unless the retention time matches a certified reference standard run under the same conditions. [1, 5] [Lab]

What LC-MS identity means

LC-MS couples the same kind of separation to a mass spectrometer, which reports the mass of the molecules in each peak. If the measured mass matches the theoretical mass of the labeled peptide within a set tolerance, identity is supported. The Open Peptide Standard uses ±0.5 Da, or ±10 ppm by high-resolution MS. [1] [Policy] Mass spectrometry is how doping and forensic labs caught products that looked like known secretagogues but carried an extra glycine at one end, a change a purity percentage would never reveal. [3] Black-market growth-hormone products have likewise turned out to be variants of the labeled molecule. [6] [Lab, forensic]

How a product passes one test and fails the other

Swapped or modified peptide, high HPLC purity. If a seller ships a different or modified peptide that was purified well, HPLC can show a single tall peak. Only a mass check, or a reference-standard comparison, shows it is the wrong molecule. [3, 6] [Lab]
Right mass, poor product. LC-MS can confirm the expected mass while the vial still carries deletion or insertion sequences, oxidized forms, or protecting-group adducts left from synthesis. These need a purity method with impurity reporting. [4] [Lab]
Same mass, different molecule. Some synthesis by-products, such as racemized (D-amino-acid) forms, have exactly the same mass as the intended peptide. They separate, if at all, only by chromatography. [4] [Lab]
Invisible fillers. Bulking agents and salts can make up a large share of the powder without showing in a UV purity figure. [2, 7] [Lab]

Neither test measures how much peptide is in the vial

Purity is a ratio and identity is a yes or no. The amount of peptide in a vial (content, or strength) needs a separate quantitative assay against a reference standard, or amino acid analysis. The Open Peptide Standard lists vial content by HPLC assay against a reference standard as a third core test, and net peptide content by amino acid analysis as an extended test. [1, 5, 8] [Lab, Policy] See the net-content guide for why this matters.

How regulated drugs handle this

For FDA-approved synthetic peptides, generic makers have to identify and limit peptide-related impurities against the reference drug, using orthogonal methods, because new impurities can change immunogenicity. [9, 4] [Regulatory] No such requirement applies to products sold for research use only. This page does not name, rank or recommend any testing laboratory.

Evidence levels used on this page

[Regulatory] FDA, USP or WADA primary document or an FDA-approved label. [Controlled study] randomized trial or systematic review of trials. [Observational] surveillance, pharmacovigilance or cohort data. [Lab] analytical, cell or animal work. [Guidance] professional-society guidance. [Policy] Open Peptide Project published policy.

How to read a peptide COA, Net peptide content vs. gross powder weight, Inside blind retail batch testing, Counterfeit and mislabeled gray-market peptides

References

Open Peptide Project. Testing standard (Open Peptide Standard, Protocol v1.1), read Oct 27, 2026. https://openpeptideproject.org/standard/
Choules MP, et al. NMR reveals an undeclared constituent in custom synthetic peptides. J Pharm Biomed Anal. 2020. PMID 31671336.
Gajda et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal. 2019. PMID 30136411.
D'Hondt M, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014. PMID 25044089.
McCarthy et al. Reference standards to support quality of synthetic peptide therapeutics. Pharm Res. 2023. PMID 36949371.
Krug O, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018. PMID 29864719.
Mrozik W, et al. Determination of counter-ions in synthetic peptides by ion chromatography, capillary isotachophoresis and capillary electrophoresis. J Pept Sci. 2012. PMID 22252914.
Hoofnagle AN, et al. Recommendations for the generation, quantification, storage, and handling of peptides used for mass spectrometry-based assays. Clin Chem. 2016. PMID 26719571.
US FDA guidance. ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin (docket FDA-2017-D-5767).

Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.